These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20655210)

  • 21. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
    Yang Y; Shen Y; Liu H; Yao X
    J Chem Inf Model; 2011 Dec; 51(12):3235-46. PubMed ID: 22097958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.
    Bukhtiyarova M; Karpusas M; Northrop K; Namboodiri HV; Springman EB
    Biochemistry; 2007 May; 46(19):5687-96. PubMed ID: 17441692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The kinetics of binding to p38MAP kinase by analogues of BIRB 796.
    Regan J; Pargellis CA; Cirillo PF; Gilmore T; Hickey ER; Peet GW; Proto A; Swinamer A; Moss N
    Bioorg Med Chem Lett; 2003 Sep; 13(18):3101-4. PubMed ID: 12941343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
    Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of Molecular Interactions and Protein Rearrangement in the Dissociation Kinetics of p38α MAP Kinase Type-I/II/III Inhibitors.
    You W; Chang CA
    J Chem Inf Model; 2018 May; 58(5):968-981. PubMed ID: 29620886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fast Iterative Synthetic Approach toward Identification of Novel Highly Selective p38 MAP Kinase Inhibitors.
    Röhm S; Berger BT; Schröder M; Chaikuad A; Winkel R; Hekking KFW; Benningshof JJC; Müller G; Tesch R; Kudolo M; Forster M; Laufer S; Knapp S
    J Med Chem; 2019 Dec; 62(23):10757-10782. PubMed ID: 31702918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and characterization of N', N"-diaryl ureas as p38 kinase inhibitors.
    Kulkarni RG; Laufer S; Mangannavar C; Garlapati A
    Med Chem; 2013 Mar; 9(2):213-21. PubMed ID: 22946566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor design.
    Han S; Mistry A; Chang JS; Cunningham D; Griffor M; Bonnette PC; Wang H; Chrunyk BA; Aspnes GE; Walker DP; Brosius AD; Buckbinder L
    J Biol Chem; 2009 May; 284(19):13193-201. PubMed ID: 19244237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase.
    Sack JS; Kish KF; Pokross M; Xie D; Duke GJ; Tredup JA; Kiefer SE; Newitt JA
    Acta Crystallogr D Biol Crystallogr; 2008 Jul; D64(Pt 7):705-10. PubMed ID: 18566506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure of mitogen-activated protein kinase kinase 1 in the DFG-out conformation.
    Nakae S; Kitamura M; Fujiwara D; Sawa M; Shirai T; Fujii I; Tada T
    Acta Crystallogr F Struct Biol Commun; 2021 Dec; 77(Pt 12):459-464. PubMed ID: 34866601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unique MAP Kinase binding sites.
    Akella R; Moon TM; Goldsmith EJ
    Biochim Biophys Acta; 2008 Jan; 1784(1):48-55. PubMed ID: 18068683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5-amino-pyrazoles as potent and selective p38α inhibitors.
    Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Designing an orally available nontoxic p38 inhibitor with a fragment-based strategy.
    Guarnieri F
    Methods Mol Biol; 2015; 1289():211-26. PubMed ID: 25709042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
    Badrinarayan P; Sastry GN
    J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the hinge glycine flip and the activation loop: novel approach to potent p38α inhibitors.
    Martz KE; Dorn A; Baur B; Schattel V; Goettert MI; Mayer-Wrangowski SC; Rauh D; Laufer SA
    J Med Chem; 2012 Sep; 55(17):7862-74. PubMed ID: 22897496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3.
    Angell RM; Atkinson FL; Brown MJ; Chuang TT; Christopher JA; Cichy-Knight M; Dunn AK; Hightower KE; Malkakorpi S; Musgrave JR; Neu M; Rowland P; Shea RL; Smith JL; Somers DO; Thomas SA; Thompson G; Wang R
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1296-301. PubMed ID: 17194588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced selectivity profile of pyrazole-urea based DFG-out p38alpha inhibitors.
    Liu H; Kuhn C; Feru F; Jacques SL; Deshmukh GD; Ye P; Rennie GR; Johnson T; Kazmirski S; Low S; Coli R; Ding YH; Cheng AC; Tecle H; English JM; Stanton R; Wu JC
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4885-91. PubMed ID: 20620059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.
    Gill AL; Frederickson M; Cleasby A; Woodhead SJ; Carr MG; Woodhead AJ; Walker MT; Congreve MS; Devine LA; Tisi D; O'Reilly M; Seavers LC; Davis DJ; Curry J; Anthony R; Padova A; Murray CW; Carr RA; Jhoti H
    J Med Chem; 2005 Jan; 48(2):414-26. PubMed ID: 15658855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.